These findings highlight the crucial role of SIRT1‐mediated NAMPT deacetylation on obesity‐induced muscle dysfunction, suggesting targeting NAMPT has the potential to reverse the obesity induced muscle dysfunction and provide effective treatment options for OSA. The gene discussed is SIRT1; the disease is obesity disorder.